Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study using a genetic mouse model found that S. aureus-driven dysbiosis sustains inflammatory skin side effects from EGFR inhibitors, suggesting prophylactic antibiotic treatment may reduce rash severity without fixing barrier defects.

In this case report, a 65-year-old woman with non-small cell lung cancer experienced scarring alopecia with papulo-pustular lesions on the scalp due to gefitinib treatment, marking it as a rare instance of gefitinib-induced erosive pustular dermatosis of the scalp.

This study found that serum GPER-1 levels were significantly higher in patients with androgenetic alopecia compared to healthy controls, suggesting a potential role in the condition's pathogenesis, independent of gender.

This study reported that EGFR inhibitor therapy in lung and head/neck cancer patients was associated with acneiform eruptions and severe skin dryness, which rarely necessitate discontinuation of treatment and can be managed symptomatically.

This study found that serum GPER-1 levels may serve as a biomarker for differentiating androgenetic alopecia from telogen effluvium and healthy controls, although its ability to distinguish between AGA and TE is limited.

This review discusses the classification, pathogenesis, and management of skin, hair, nail, and mucosal changes due to EGFR inhibitors, emphasizing the importance of informing patients to improve therapy compliance.

EGFR cancer drugs often cause a rash, which can lead to distress and isolation, but may also improve outcomes for some cancer patients. Current treatments for the rash are limited, but a compound called menadione shows promise.

Skin problems like acne, dry skin, and nail and hair changes are common in patients taking EGFR inhibitors.

This study discusses two cases of acneiform skin eruptions associated with the use of the EGFR inhibitor ZD1839 in prostate cancer treatment, emphasizing the need for dermatologists to be aware of potential skin reactions.

This study observed that severe bronchitis may occur in individuals with anhidrotic ectodermal dysplasia when exposed to a dusty environment, potentially due to abnormalities in the bronchial mucosa.

This study reports an increase in the use of tamsulosin/finasteride for benign prostatic syndrome in Germany but highlights that reliable comparisons with monotherapies are lacking due to study design deficiencies.

This case report describes a woman who developed extensive nonscarring inflammatory hair loss after two years of gefitinib treatment, highlighting potential cutaneous side effects associated with epidermal growth factor receptor blockers.

This case report describes a 57-year-old Japanese female who developed scarring alopecia linked to gefitinib, an EGFR inhibitor, with improvement in hair loss after reducing the drug dosage.

This review discusses Ganser syndrome as a rare and misunderstood disorder within psychiatric practice, noting its exclusion from the DSM-5 and potential dual origins as organic or psychogenic.

Glycerin in hand cream can cause allergic skin reactions.

This study found a significant association between patients' sex of rearing and external genitalia in those with gonadal dysgenesis, while noting lower testosterone levels compared to controls.

This study describes three cases of acneiform eruptions from EGFR inhibitors that improved with topical recombinant human EGF, suggesting its potential as a treatment option for this side effect.

This study reported that the most common skin side effect of epidermal growth factor receptor inhibitors was a papulopustular rash, treatable with symptom-targeted therapies, while drug suspension was rarely needed.

Self-induced vomiting in anorexia can lead to rare gout complications.

The study found that patients with androgenetic alopecia had higher serum GPER-1 levels, which were associated with disease severity and duration, indicating a potential estrogen-independent role of GPER-1 in the condition's pathogenesis.

This paper describes the PRIDE syndrome associated with epidermal growth factor receptor inhibitors but reports no new clinical results.

This study found that EGFR-targeted cancer therapy can cause skin toxicities by disrupting epidermal signaling, allowing microbiota invasion and inflammation, but identified a potential treatment approach using FGF7 or SOS expression to restore barrier integrity.

This review describes the approved use and adverse effects of gefitinib in patients with advanced non-small cell lung cancer, without presenting new clinical findings.

This study reports two cases of erlotinib-induced erosive pustular dermatosis of the scalp in patients with non-small cell lung cancer, emphasizing the need for dermatological monitoring during EGFR inhibitor therapy.

This source outlines common health issues in weanling gerbils, including skin infections often tied to beta-hemolytic Staphylococcus aureus, and obesity-related conditions like diabetes, as well as respiratory infections and musculoskeletal problems, without detailing specific new study results.

A woman with anorexia developed gout from self-induced vomiting.

The document concludes that using gadolinium-based contrast agents during MRI can be linked to Nephrogenic Systemic Fibrosis in patients with severe kidney disease.

This review discusses the adverse skin effects of EGFR inhibitors used in cancer treatment, exploring their mechanisms and offering strategies for prevention and management, but reports no new experimental findings.

This report discusses two cases where patients continued EGFR inhibitor therapy while receiving topical treatments for SDRIFE, highlighting the importance of dermatologists in managing such cutaneous adverse events without stopping cancer treatment.

In this rodent study, the researchers found that different hormone therapies affected gut microbiota and goblet cell counts, with notable microbial shifts observed between groups receiving estrogen with and without an orchiectomy, linked to estrogen metabolism.